GlobeNewswire Inc.··Not SpecifiedTaysha Gene Therapies Posts $109M Loss, Advances Rett Syndrome Therapy
Taysha Gene Therapies reported $109M 2025 loss while advancing TSHA-102 gene therapy for Rett syndrome with positive safety data and FDA regulatory alignment through 2028.
TSHAFDA approvalclinical trial